briefglance.com
Palisade Bio Highlights PALI-2108 Potential for Fibrostenotic Crohn's Disease at NYAS Symposium
Fibrosis and strictures (fibrostenotic disease) are important unmet problems in Crohn’s disease with limited medical options. An investigational drug that targets PDE4 locally could potentially offer a new approach if later trials show benefit and acceptable tolerability.
Patients with fibrostenotic Crohn’s disease or those interested in new anti-fibrotic/anti-inflammatory therapies, clinicians treating IBD, and researchers working on drug development for fibrotic complications.
What To Know
Palisade Bio presented on PALI-2108, a locally bioactivated PDE4 inhibitor prodrug, highlighting Phase 1a and Phase 1b results and plans to advance to Phase 2 studies in ulcerative colitis and fibrostenotic Crohn’s disease.
The talk emphasized unmet needs in fibrostenotic Crohn’s disease (fibrosis and strictures) and the company’s strategy to improve PDE4 pharmacology and tolerability via a prodrug platform.
PALI-2108 is described as investigational; the article reports early-stage clinical progress (Phase 1 trials completed with positive signals) but does not provide detailed efficacy or safety data. No treatment recommendations or specific trial outcomes are given in the source text.
If you’re tracking emerging treatments for fibrotic complications of IBD, this is a development to watch as PALI-2108 moves toward Phase 2 testing. For clinical decisions or personal treatment changes, discuss with your care team and consider that Phase 2 studies will be needed to better define benefits and risks.
This coverage summarizes a company presentation at a scientific symposium and mentions Phase 1 results and plans for Phase 2. Early positive signals in Phase 1 do not guarantee later success; detailed trial data, peer-reviewed publications, and regulatory review will be needed to judge safety and effectiveness.
The article is a market/business-focused summary rather than a full clinical report.
